What is Ascribe Bioscience?
Founded in 2017 and headquartered in Ithaca, New York, Ascribe Bioscience operates at the intersection of advanced biotechnology and sustainable agriculture. The company specializes in the development of environmentally-friendly biopesticides, providing a critical alternative to synthetic chemical agents that have historically dominated the crop protection market. By leveraging natural biological processes, Ascribe Bioscience addresses the growing global demand for sustainable farming solutions that do not compromise on efficacy or yield. Their market position is bolstered by a commitment to rigorous scientific validation, positioning them as a key player in the transition toward regenerative agricultural practices.
How much funding has Ascribe Bioscience raised?
Ascribe Bioscience has raised a total of $15M across 1 funding round:
Stock/Share Issuance
$15M
Stock/Share Issuance (2025): $15M, investors not publicly disclosed
Key Investors in Ascribe Bioscience
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Ascribe Bioscience?
Following this major strategic investment, Ascribe Bioscience is expected to scale its operational capacity and expand its commercial footprint. The enterprise-level funding will likely be directed toward optimizing manufacturing processes and navigating the complex regulatory pathways required for broader market adoption. As the agricultural sector faces increasing pressure to reduce chemical footprints, Ascribe Bioscience is strategically aligned to capture significant market share. Future growth will likely focus on diversifying their product pipeline and establishing partnerships with large-scale agricultural distributors to integrate their biopesticide solutions into mainstream farming operations globally.
See full Ascribe Bioscience company page
